Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus

Journal of the Formosan Medical Association

Volumn 112, Issue 3, 2013, Pages 144-150

  Lu, Chieh Hsiang ^a   Wu, Ta Jen ^b   Shih, Kuang Chung ^c   Ni, Ewan ^d   Reed, Victoria ^e   Yu, Maria ^d   Sheu, Wayne H H ^f   Chuang, Lee Ming ^g  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d ELI LILLY AND COMPANY   (United States)

^e ELI LILLY AUSTRALIA PTY LTD   (Australia)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Glucagon like peptide 1; Taiwan; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 84875385687     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2012.02.027     Document Type: Article

References (23)

1. Diabetes mellitus: fact sheet 312 2008, World Health Organization, WHO, Geneva.
2. Chan J.C., Malik V., Jia W., Kadowaki T., Yajnik C.S., Yoon K.H., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-2140.
3. Yoon K.H., Lee J.H., Kim J.W., Cho J.H., Choi Y.H., Ko S.H., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006, 368:1681-1688.
4. Chen K.T., Chen C.J., Gregg E.W., Engelgau M.M., Narayan K.M. Prevalence of type 2 diabetes mellitus in Taiwan: ethnic variation and risk factors. Diabetes Res Clin Pract 2001, 51:59-66.
5. Greig N.H., Holloway H.W., De Ore K.A., Jani D., Wang Y., Zhou J., et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999, 42:45-50.
6. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999, 48:1026-1034.
7. Nielsen L.L., Baron A.D. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2003, 4:401-405.
8. Parkes D.G., Pittner R., Jodka C., Smith P., Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50:583-589.
9. Stonehouse A., Okerson T., Kendall D., Maggs D. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev 2008, 4:101-109.
10. DeFronzo R.A., Okerson T., Viswanathan P., Guan X., Holcombe J.H., MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008, 24:2943-2952.
11. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D., Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
12. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
13. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
14. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
15. Pi-Sunyer F.X. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med 2009, 121:94-107.
16. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G., GWAA Study Group Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
17. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
18. Barnett A.H., Burger J., Johns D., Brodows R., Kendall D.M., Roberts A., et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007, 29:2333-2348.
19. Gao Y., Yoon K.H., Chuang L.M., Mohan V., Ning G., Shah S., et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009, 83:69-76.
20. Regional Office for the Western Pacific, International Association for the Study of Obesity, International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment 2000, World Health Organization, Health Communications Australia Pty Ltd, Balmain, NSW.
21. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
22. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
23. Lyu L.C., Lin C.F., Chang F.H., Chen H.F., Lo C.C., Ho H.F. Meal distribution, relative validity and reproducibility of a meal-based food frequency questionnaire in Taiwan. Asia Pac J Clin Nutr 2007, 16:766-776.